MARKET

RARE

RARE

Ultragenyx Pharm
NASDAQ
26.85
-0.12
-0.43%
Opening 15:39 08/12 EDT
OPEN
26.79
PREV CLOSE
26.96
HIGH
27.00
LOW
26.11
VOLUME
700.23K
TURNOVER
--
52 WEEK HIGH
39.89
52 WEEK LOW
18.29
MARKET CAP
2.65B
P/E (TTM)
-4.5986
1D
5D
1M
3M
1Y
5Y
1D
Ultragenyx (RARE) Q2 2026 Earnings Call Transcript
The Motley Fool · 13h ago
Prime Medicine: An Initial Prognosis
Seeking Alpha · 1d ago
Ultragenyx Settles DOJOLVI Patent Dispute with Esjay
TipRanks · 1d ago
Ultragenyx Pharmaceutical And Baylor Research Institute Reach Settlement Agreement With Esjay Pharma To Resolve Patent Litigation Related To The Company’s DOJOLVI Oral Liquid; Esjay Granted Non-Exclusive License For Generic DOJOLVI From 2033
Benzinga · 1d ago
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Evercore ISI
TipRanks · 2d ago
Weekly Report: what happened at RARE last week (0803-0807)?
Weekly Report · 2d ago
Ultragenyx Pharma Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Reiterates Buy on Ultragenyx Pharmaceutical, Maintains $50 Price Target
Benzinga · 2d ago
More
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company's clinical-stage pipeline consists of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its products include Crysvita (burosumab), Mepsevii (vestronidase alfa), Dojolvi (triheptanoin), and Evkeeza (evinacumab). Crysvita is used for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. Mepsevii is used for the treatment of children and adults with mucopolysaccharidosis VII, or MPS VII, also known as Sly syndrome. Dojolvi is used for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders, or LC-FAOD. Evkeeza is used for the treatment of homozygous familial hypercholesterolemia, or HoFH.

Webull offers Ultragenyx Pharmaceutical Inc stock information, including NASDAQ: RARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RARE stock methods without spending real money on the virtual paper trading platform.